ClinicalTrials.gg
CompletedNCT05090904Updated Mar 12, 2026Results posted

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

A Phase 2 interventional study of Brensocatib and Placebo in Cystic Fibrosis, sponsored by Insmed Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
303rd of 517
29 · median 36
Started
2021
with 35 others
Phase 2
103 of 717
10 open now
Registered
597th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 303rd largest by enrollment of the 517 interventional ones that give a count, is one of 36 that started in 2021, is one of 103 in phase 2, and was the 597th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
  • Brensocatib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥18 years of age at the time of signing the .
  • Male or female participants with a confirmed diagnosis of CF related lung disease:

    1. Percent predicted (ppFEV1) between 40% to 90% (inclusive) at Screening Visit and at Baseline.
    2. Stable CF treatment for at least 30 days before screening and willing to remain on a stable regimen throughout the treatment period.
  • Has a ≥18 kg/m\^2.
  • Male and female participants must use that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male participants, who are not sterile, with female partners of must be using effective contraception from Day 1 to at least 90 days after the last dose.
    2. Women must be (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or using highly effective contraception methods (i.e., methods that alone or in combination achieve \<1% unintended pregnancy rates per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose.
  • Female participants of childbearing potential must have a negative serum pregnancy test at Screening.
  • Male participants with pregnant or nonpregnant women of childbearing potential partners must use a condom.

Exclusion criteria

Exclusion Criteria:

  • Severe or unstable CF, per Investigator's judgement.
  • Currently being treated for allergic bronchopulmonary aspergillosis or nontuberculous mycobacteria or tuberculosis.
  • Active and current infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • History of in the past 5 years, except completely treated in situ carcinoma of the cervix and completely treated non- squamous or basal cell carcinoma of the skin.
  • Established diagnosis of viral infection or positive for hepatitis B surface antigen (HBsAg) at Screening.
  • Established diagnosis of virus (HCV) infection at Screening. Participants positive for hepatitis C antibody are eligible only if HCV RNA is negative.
  • History of (HIV) infection.
  • Acute upper or lower respiratory tract infection, pulmonary exacerbation, or changes in therapy (including intravenous and oral antibiotics) for pulmonary disease within 4 weeks prior to Day 1 (administration of the first dose of study drug). Participants meeting this criterion could be rescreened 4 weeks after resolution of symptoms.
  • History of prolonged /QTc interval with QTcF >480 millisecond (msec) at Screening.
  • History of solid organ or hematological transplantation.
  • Have diagnosed periodontal disease and are either:

    1. Currently treated by a dentist for this condition or
    2. Expected to have periodontal disease-related procedures within the study period.
  • Received any within 4 weeks prior Screening.
  • Ongoing participation in another therapeutic clinical study or prior participation in an drug study within 90 days prior to Screening.
  • Known history of to brensocatib or any of its .
  • Use of any immunomodulatory agents within 4 weeks before the Screening Visit is prohibited during the study through end of study (including, but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, interferon gamma (IFN-γ], and azathioprine).
  • Continuous use of high-dose non-steroidal anti-inflammatory drugs (NSAIDs) is prohibited during the study through end of study.
  • History of alcohol, medication, or illicit drug abuse.
  • Current smoker, as defined by Centers for Disease Control and Prevention: An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Brensocatib 10 mg

    Participants received brensocatib at a dose of 10 mg once per day for 28 days.

    Drug: Brensocatib

  • Experimental
    Brensocatib 25 mg

    Participants received brensocatib at a dose of 25 mg once per day for 28 days.

    Drug: Brensocatib

  • Experimental
    Brensocatib 40 mg

    Participants received brensocatib at a dose of 40 mg once per day for 28 days.

    Drug: Brensocatib

  • Placebo comparator
    Placebo

    Participants received a placebo matching brensocatib once per day for 28 days.

    Drug: Placebo

Interventions

  • Oral tablet

    Also known as: INS1007

  • DrugPlacebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1

  2. Cmax of Brensocatib on Day 28

    Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28

  3. Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1

  4. Tmax of Brensocatib on Day 28

    Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28

  5. Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1

    Time frame: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1

  6. AUC0-24 of Brensocatib in Plasma on Day 28

    Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 28

  7. Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28

    Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28

  8. Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

    A TEAE is defined as any adverse event (AE) that occurred after the first dose of study investigational medicinal product (IMP) and within 28 days after the last dose of study IMP.

    Time frame: Up to Day 56

Secondary outcomes

  1. Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib Cmax After Administration of Brensocatib on Days 1 and 28

    Analysis of dose dependency for brensocatib Cmax was performed using a power law model. The logarithm of the Cmax was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.

    Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose

  2. Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUC0-24 After Administration of Brensocatib on Days 1 and 28

    Analysis of dose dependency for brensocatib AUC0-24 was performed using a power law model. The logarithm of the AUC0-24 was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.

    Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose

  3. AUClast of Brensocatib in Plasma on Days 1 and 28

    Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose

  4. Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUClast, After Administration of Brensocatib on Days 1 and 28

    Analysis of dose dependency for brensocatib AUClast was performed using a power law model. The logarithm of the AUClast was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.

    Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose

07

Results

Posted Mar 12, 2026

Participant flow

Participants took part in the study at investigational sites in the United States.

Participant flow — Overall Study
MilestoneBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlacebo
Started8885
Completed8885
Not completed0000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Brensocatib on Day 1
Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1
nanograms per milliliter (ng/mL)Brensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Maximum Plasma Concentration (Cmax) of Brensocatib on Day 162.4 ± 41.3136 ± 25.9338 ± 17.7
PrimaryCmax of Brensocatib on Day 28
Time frame:
Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Reported as:
Geometric mean · ng/mL
Cmax of Brensocatib on Day 28
ng/mLBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Cmax of Brensocatib on Day 2886.2 ± 33.1234 ± 37.5469 ± 34.0
PrimaryTime to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1
Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1
hoursBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 12.0 (1.0 to 24.8)1.5 (1.0 to 4.1)1.5 (0.6 to 24.9)
PrimaryTmax of Brensocatib on Day 28
Time frame:
Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Reported as:
Median · hours
Tmax of Brensocatib on Day 28
hoursBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Tmax of Brensocatib on Day 281.9 (0.5 to 4.0)2.0 (1.0 to 4.0)2.0 (1.0 to 4.0)
PrimaryArea Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1
Time frame:
Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Reported as:
Geometric mean · hours*ng/mL
Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1
hours*ng/mLBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1792 ± 49.51600 ± 22.03510 ± 35.0
PrimaryAUC0-24 of Brensocatib in Plasma on Day 28
Time frame:
Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 28
Reported as:
Geometric mean · hours*ng/mL
AUC0-24 of Brensocatib in Plasma on Day 28
hours*ng/mLBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
AUC0-24 of Brensocatib in Plasma on Day 281050 ± 33.13640 ± 32.75950 ± 40.4
PrimaryElimination Half-life (t1/2) of Brensocatib in Plasma on Day 28
Time frame:
Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Reported as:
Geometric mean · hours
Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28
hoursBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 2829.6 ± 16.532.4 ± 23.036.0 ± 39.5
PrimaryNumber of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)

A TEAE is defined as any adverse event (AE) that occurred after the first dose of study investigational medicinal product (IMP) and within 28 days after the last dose of study IMP.

Time frame:
Up to Day 56
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
ParticipantsBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlacebo
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)4542
SecondaryDose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib Cmax After Administration of Brensocatib on Days 1 and 28

Analysis of dose dependency for brensocatib Cmax was performed using a power law model. The logarithm of the Cmax was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.

Time frame:
Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose
Reported as:
Number · log(ng/ml) per log(mg)
Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib Cmax After Administration of Brensocatib on Days 1 and 28
log(ng/ml) per log(mg)Brensocatib 10 mg to 40 mg
Day 11.168 (0.97 to 1.37)
Day 281.206 (1.00 to 1.41)
SecondaryDose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUC0-24 After Administration of Brensocatib on Days 1 and 28

Analysis of dose dependency for brensocatib AUC0-24 was performed using a power law model. The logarithm of the AUC0-24 was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.

Time frame:
Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
Reported as:
Number · log(ng*h/mL) per log(mg)
Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUC0-24 After Administration of Brensocatib on Days 1 and 28
log(ng*h/mL) per log(mg)Brensocatib 10 mg to 40 mg
Day 11.033 (0.80 to 1.26)
Day 281.267 (1.05 to 1.48)
SecondaryAUClast of Brensocatib in Plasma on Days 1 and 28
Time frame:
Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose
Reported as:
Geometric mean · hours*ng/mL
AUClast of Brensocatib in Plasma on Days 1 and 28
hours*ng/mLBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mg
Day 1792 ± 49.51600 ± 22.03510 ± 35.0
Day 282210 ± 40.68220 ± 44.113700 ± 58.6
SecondaryDose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUClast, After Administration of Brensocatib on Days 1 and 28

Analysis of dose dependency for brensocatib AUClast was performed using a power law model. The logarithm of the AUClast was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.

Time frame:
Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose
Reported as:
Number · log(ng*h/mL) per log(mg)
Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUClast, After Administration of Brensocatib on Days 1 and 28
log(ng*h/mL) per log(mg)Brensocatib 10 mg to 40 mg
Day 11.033 (0.80 to 1.26)
Day 281.334 (1.05 to 1.61)

Adverse events

Collected over Up to Day 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brensocatib 10 mg0/8 (0%)0/8 (0%)4/8 (50%)
Brensocatib 25 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
Brensocatib 40 mg0/8 (0%)1/8 (12.5%)4/8 (50%)
Placebo0/5 (0%)0/5 (0%)2/5 (40%)
Most frequent serious events
Most frequent serious events
EventBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlacebo
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/80/81/80/5
Most frequent other events
Showing 10 of 33
Most frequent other events
EventBrensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlacebo
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/80/81/80/5
Sputum increasedRespiratory, thoracic and mediastinal disorders2/80/80/80/5
HeadacheNervous system disorders0/82/80/81/5
Abdominal painGastrointestinal disorders0/80/81/81/5
Abdominal pain upperGastrointestinal disorders0/80/80/81/5
GastroenteritisGastrointestinal disorders0/80/80/81/5
HyperhidrosisSkin and subcutaneous tissue disorders0/80/80/81/5
COVID-19Infections and infestations0/81/81/80/5
CoughRespiratory, thoracic and mediastinal disorders1/81/80/80/5
LymphadenopathyBlood and lymphatic system disorders0/81/80/80/5

Baseline characteristics

Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Brensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlaceboTotal
Mean38.3 ± 14.8642.9 ± 16.5434.6 ± 15.9534.6 ± 9.7937.9 ± 14.59
Sex: Female, Male
Sex: Female, Male(Participants)Brensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlaceboTotal
Female252211
Male636318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlaceboTotal
Hispanic or Latino11114
Not Hispanic or Latino00000
Unknown or Not Reported777425
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brensocatib 10 mgBrensocatib 25 mgBrensocatib 40 mgPlaceboTotal
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American00101
White786526
More than one race00000
Unknown or Not Reported10001
08

Study locations

14 sites
  • USA001
    Gainesville, Florida 32610, United States
  • USA016
    Augusta, Georgia 30912, United States
  • USA025
    Glenview, Illinois 60025, United States
  • USA011
    Boston, Massachusetts 02115, United States
  • USA023
    Ann Arbor, Michigan 48109, United States
  • USA002
    St Louis, Missouri 63101, United States
  • USA022
    New York, New York 10032, United States
  • USA008
    Cleveland, Ohio 44106, United States
  • USA006
    Cleveland, Ohio 44195, United States
  • USA018
    Portland, Oregon 97239, United States
  • USA009
    Charleston, South Carolina 29425, United States
  • USA017
    Nashville, Tennessee 37232, United States
  • USA004
    Dallas, Texas 75390, United States
  • USA003
    Tyler, Texas 75708, United States
09

References and documents

Publications

  • Konstan MW, Tolle JJ, DiMango E, Flume PA, Usansky H, Teper A, Ramirez CN, Flarakos J, Basso J, Li S, Vergara M. A Phase IIa, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Brensocatib in Adults with Cystic Fibrosis. Clin Pharmacokinet. 2025 Oct;64(10):1561-1574. doi: 10.1007/s40262-025-01550-z. Epub 2025 Aug 3. PubMed 40753522 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Nov 2022, 11 months.

Results were first posted in Mar 2026, 3 years 4 months after primary completion. A results delay was requested in Oct 2023.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 11 months is below that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Oct 25, 2021
StartActual
Nov 30, 2021
Primary completionActual
Nov 1, 2022
CompletionActual
Nov 1, 2022
Results delay requested
Oct 31, 2023
Results first posted
Mar 12, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05090904
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Nov 30, 2021
Primary completion
Nov 1, 2022
Completion
Nov 1, 2022
Results posted
Mar 12, 2026
Last update
Mar 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion